Efficacy of a new pharmacokinetically enhanced formulation of amoxicillin/clavulanate (2000/125 mg) in adults with community-acquired pneumonia caused by Streptococcus pneumoniae, including penicillin-resistant strains. (Q47861588)
Jump to navigation
Jump to search
scientific article published in February 2005
| Language | Label | Description | Also known as |
|---|---|---|---|
| English | Efficacy of a new pharmacokinetically enhanced formulation of amoxicillin/clavulanate (2000/125 mg) in adults with community-acquired pneumonia caused by Streptococcus pneumoniae, including penicillin-resistant strains. |
scientific article published in February 2005 |
Statements
Efficacy of a new pharmacokinetically enhanced formulation of amoxicillin/clavulanate (2000/125 mg) in adults with community-acquired pneumonia caused by Streptococcus pneumoniae, including penicillin-resistant strains (English)
Michael R Jacobs
Brian Wynne
Monique Twynholm
1 February 2005